- Home
- ARGX vs ALL Comparison
ARGX vs ALL Comparison
Compare ARGX & ALL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- ALL
- Stock Information
- Founded
- ARGX 2008
- ALL 1931
- Country
- ARGX Netherlands
- ALL United States
- Employees
- ARGX N/A
- ALL N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- ALL Property-Casualty Insurers
- Sector
- ARGX Health Care
- ALL Finance
- Exchange
- ARGX Nasdaq
- ALL Nasdaq
- Market Cap
- ARGX 48.2B
- ALL 53.1B
- IPO Year
- ARGX 2017
- ALL 1993
- Fundamental
- Price
- ARGX $830.94
- ALL $195.33
- Analyst Decision
- ARGX Strong Buy
- ALL Buy
- Analyst Count
- ARGX 18
- ALL 15
- Target Price
- ARGX $813.82
- ALL $227.43
- AVG Volume (30 Days)
- ARGX 335.2K
- ALL 1.4M
- Earning Date
- ARGX 10-30-2025
- ALL 11-05-2025
- Dividend Yield
- ARGX N/A
- ALL 2.05%
- EPS Growth
- ARGX N/A
- ALL 93.10
- EPS
- ARGX 18.75
- ALL 21.24
- Revenue
- ARGX $3,120,821,000.00
- ALL $66,218,000,000.00
- Revenue This Year
- ARGX $81.74
- ALL N/A
- Revenue Next Year
- ARGX $31.91
- ALL $7.35
- P/E Ratio
- ARGX $39.68
- ALL $9.18
- Revenue Growth
- ARGX 88.04
- ALL 9.81
- 52 Week Low
- ARGX $510.06
- ALL $176.00
- 52 Week High
- ARGX $838.07
- ALL $215.70
- Technical
- Relative Strength Index (RSI)
- ARGX 75.79
- ALL 35.04
- Support Level
- ARGX $793.60
- ALL $203.28
- Resistance Level
- ARGX $808.43
- ALL $209.91
- Average True Range (ATR)
- ARGX 15.74
- ALL 4.04
- MACD
- ARGX 3.08
- ALL -1.58
- Stochastic Oscillator
- ARGX 95.87
- ALL 3.09
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.